Uday R. Popat, MD, discusses the role of JAK inhibitors in patients with myeloproliferative neoplasms.
Uday R. Popat, MD, professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of JAK inhibitors in patients with myeloproliferative neoplasms (MPNs).
The bets data to confirm the role of JAK inhibitors, such as ruxolitinib (Jakafi) and fedratinib (Inrebic) which are both FDA-approved for MPN indications, in the transplant-eligible population would be from a randomized clinical trial in which patients receive the JAK inhibitor or a different therapy. While this data is not yet available, Popat says we do have retrospective data that appear promising.
In a retrospective study of about 100 patients, a JAK inhibitor was given to patients prior to transplant, and the outcomes appeared better among those who went on and received transplant after the JAK inhibitor, Popat says. Similar data from the Seattle Group also demonstrated ruxolitinib with a conditioning regimen induced promising survival data.
Weighing the Triggers for Initiating JAK2 Inhibition Therapy in MF
March 23rd 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
Participants Discuss Treating a Patient With Myelofibrosis and Anemia
March 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed with participants which symptoms of myelofibrosis impact their quality of life and how they would treat a patient experiencing anemia.
Read More
Challenges of Interpreting JAK Inhibitor Data for Real-World Myelofibrosis Care
March 4th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.
Read More